Steven K Albanese

This inventor holds 7 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Nimbus Saturn, Inc., Nimbus Clotho, Inc.. Active years: 2021-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven K Albanese. Retrieved from https://idiyas.com/inventor/steven-k-albanese

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 10.0

ph-index = 4

Forward Citations = 32(Granted Patents)

Company Filing History:

Years Active: 2021-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331046 - CTPS1 inhibitors and uses thereof (2025-06-17),

2. 12215105 - HPK1 antagonists and uses thereof (2025-02-04),

3. 11548890 - HPK1 antagonists and uses thereof (2023-01-10),

4. 11078201 - Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists (2021-08-03),

5. 11034694 - Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists (2021-06-15),

6. 11028085 - Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists (2021-06-08),

7. 11021481 - Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists (2021-06-01),

Title: The Innovative Contributions of Steven K. Albanese

Introduction

Steven K. Albanese, an accomplished inventor based in Brooklyn, NY, has made significant strides in the field of pharmaceuticals and biochemistry. With a total of six patents to his name, Albanese has positioned himself as a leading figure in the development of innovative solutions for healthcare challenges.

Latest Patents

Albanese's latest work focuses on HPK1 antagonists, which are pivotal in the inhibition of HPK1 and the treatment of HPK1-mediated disorders. His patents provide detailed methodologies for the use of specific compounds and compositions that promise to revolutionize existing treatment protocols. The dual registration of the HPK1 antagonists highlights the importance and relevance of this research, showcasing his commitment to advancing medical science.

Career Highlights

Currently, Steven K. Albanese is affiliated with Nimbus Saturn, Inc., where he applies his expertise in developing groundbreaking therapies. His career has been marked by a series of significant achievements that demonstrate his dedication to innovation and the improvement of patient outcomes through scientific research.

Collaborations

Albanese collaborates with talented individuals such as Neelu Kaila and Ian Linney, further enhancing his research capabilities. These partnerships exemplify the collaborative nature of modern scientific inquiry, where shared knowledge and resources drive innovation forward.

Conclusion

As a prolific inventor, Steven K. Albanese continues to shape the landscape of pharmaceutical innovations. With a solid foundation of patents and an unwavering commitment to his work, Albanese is an inspiring figure in the realm of invention, contributing tremendously to the advancement of healthcare solutions.

Profile summary based on public USPTO records.